Radiopharmaceutical provider DraxImage has signed a licensing agreement with BTG for that firm's Infecton radiopharmaceutical agent. The agreement gives the Canadian firm exclusive rights to manufacture and sell the work-in-progress agent in the U.S., Canada, South America, and Europe.
Infecton is a complex of technetium-99m and ciprofloxacin and was initially discovered by Prof. Keith Britton and Kishor Solanki at St. Bartholomew's Hospital in London, U.K. DraxImage claims that Infecton is the first radiopharmaceutical to demonstrate an ability to distinguish between infection and inflammation by binding directly to bacteria in vivo.
DraxImage will undertake the formulation, manufacturing, and clinical development of Infecton and expects to file for approval by the end of 2004. The firm anticipates that Infecton will be used to image a number of medical conditions, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis, and tuberculosis.
By AuntMinnie.com staff writers
March 15, 2001
Related Reading
Draxis posts mixed Q3 results, November 8, 2000
Draxis gets Canadian OK for BrachySeed, October 10, 2000
Copyright © 2001 AuntMinnie.com
